0000899243-20-028909.txt : 20201021 0000899243-20-028909.hdr.sgml : 20201021 20201021170228 ACCESSION NUMBER: 0000899243-20-028909 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201019 FILED AS OF DATE: 20201021 DATE AS OF CHANGE: 20201021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ege David S. CENTRAL INDEX KEY: 0001829360 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 201251022 MAIL ADDRESS: STREET 1: C/O SERES THERAPEUTICS, INC. STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-19 0 0001609809 Seres Therapeutics, Inc. MCRB 0001829360 Ege David S. C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks Stock Option (Right to Buy) 32.60 2020-10-19 4 A 0 200000 0.00 A 2030-10-18 Common Stock 200000 200000 D The option will vest as to 25% of the shares on October 19, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Executive Vice President and Chief Technology Officer /s/ Thomas J. DesRosier, attorney-in-fact for David Ege 2020-10-21